Jump to section

References

Trials

Economics

Properties

Spectra

Taxonomy

Lurasidone

Targets (6)Enzymes (1)Biointeractions (6)

Identification

Name

Lurasidone

Accession Number

DB08815

Type

Small Molecule

Groups

Approved, Investigational

Description

Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. (Wikipedia)

Structure

Similar Structures

Synonyms

Lurasidona
Lurasidonum

External IDs

SM-13496

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Lurasidone Hydrochloride	O0P4I5851I	367514-88-3	NEKCRUIRPWNMLK-SCIYSFAVSA-N

Product Images

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Latuda	Tablet, film coated	40 mg/1	Oral	Avera Mc Kennan Hospital	2015-03-02	2017-11-02
Latuda	Tablet, film coated	60 mg/1	Oral	Sunovion	2013-07-12	Not applicable
Latuda	Tablet	20 mg	Oral	Sunovion	2014-04-09	Not applicable
Latuda	Tablet	80 mg	Oral	Sunovion	2012-09-05	Not applicable
Latuda	Tablet, film coated	120 mg/1	Oral	Sunovion	2012-04-26	Not applicable
Latuda	Tablet, film coated	40 mg/1	Oral	Sunovion	2010-10-28	Not applicable
Latuda	Tablet	60 mg	Oral	Sunovion	2014-03-14	Not applicable
Latuda	Tablet, film coated	80 mg/1	Oral	Sunovion	2010-10-28	Not applicable
Latuda	Tablet	40 mg	Oral	Sunovion	2012-09-06	Not applicable
Latuda	Tablet, film coated	20 mg/1	Oral	Sunovion	2011-12-07	Not applicable

Categories

UNII

22IC88528T

CAS number

367514-87-2

Weight

Average: 492.676
Monoisotopic: 492.255897106

Chemical Formula

C₂₈H₃₆N₄O₂S

InChI Key

PQXKDMSYBGKCJA-CVTJIBDQSA-N

InChI

InChI=1S/C28H36N4O2S/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2/t18-,19+,20-,21-,24+,25-/m0/s1

IUPAC Name

(1R,2S,6R,7S)-4-{[(1R,2R)-2-{[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]methyl}cyclohexyl]methyl}-4-azatricyclo[5.2.1.0²,⁶]decane-3,5-dione

SMILES

O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(CC1)C1=NSC2=CC=CC=C12

Pharmacology

Indication

Treatment of schizophrenia.

Associated Conditions

Pharmacodynamics

Lurasidone is a benzothiazol derivative that is an antagonist and binds with high affinity to Dopamine-2 (D2) (Ki = 0.994 nM), 5-HT2A (Ki = 0.47 nM) receptors, and 5-HT7 receptors (Ki = 0.495 nM). It also binds with moderate affinity to alpha-2C adrenergic receptors (Ki = 10.8 nM) and is a partial agonist at 5-HT1A receptors (Ki = 6.38 nM). Its actions on histaminergic and muscarinic receptors are negligible.

Mechanism of action

Lurasidone is an atypical antipsychotic that is a D2 and 5-HT2A (mixed serotonin and dopamine activity) to improve cognition. It is thought that antagonism of serotonin receptors can improve negative symptoms of psychoses and reduce the extrapyramidal side effects that are often associated with typical antipsychotics.

Target	Actions	Organism
AD(2) dopamine receptor	antagonist	Human
A5-hydroxytryptamine receptor 2A	antagonist	Human
U5-hydroxytryptamine receptor 7	antagonist	Human
U5-hydroxytryptamine receptor 1A	antagonist	Human
UAlpha-2C adrenergic receptor	antagonist	Human
UAlpha-2A adrenergic receptor	Not Available	Human

Absorption

Lurasidone is readily absorbed and quickly reaches maximal concentrations (Cmax) within 1-4 hours. When taken with food, there is a two-fold increase in exposure and time to maximal concentration is increased by 0.5-1.5 hours. This occurs regardless of fat or caloric content.
Bioavailability = 9-19%.

Volume of distribution

6173 L

Protein binding

~99% bound to serum proteins.

Metabolism

Lurasidone is metabolized by CYP3A4 in which its major active metabolite is referred to as ID-14283 (25% of parent exposure). Its two minor metabolites are referred to as ID14326 and ID11614 which make up 3% and 1% of parent exposure respectively. Its two non-active metabolites are referred to as ID-20219 and ID-20220.

Route of elimination

Urine (~9%) and feces (~80%)

Half life

40 mg dose= 18 hours 120 mg - 160 mg dose = 29-37 hours

Clearance

3902 mL/min

Toxicity

Not Available

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE	The therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Lurasidone.	Experimental
2,4-thiazolidinedione	The therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Lurasidone.	Investigational
2,5-Dimethoxy-4-ethylamphetamine	Lurasidone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.	Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine	Lurasidone may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.	Experimental
3,4-Methylenedioxyamphetamine	Lurasidone may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.	Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine	Lurasidone may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.	Experimental, Illicit
7-Nitroindazole	The risk or severity of adverse effects can be increased when Lurasidone is combined with 7-Nitroindazole.	Experimental
Acarbose	The therapeutic efficacy of Acarbose can be decreased when used in combination with Lurasidone.	Approved, Investigational
Acepromazine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Acepromazine.	Approved, Vet Approved
Aceprometazine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Aceprometazine.	Approved
Acetohexamide	The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Lurasidone.	Approved, Investigational, Withdrawn
Acetyl sulfisoxazole	The serum concentration of Lurasidone can be increased when it is combined with Acetyl sulfisoxazole.	Approved, Vet Approved
Adipiplon	The risk or severity of adverse effects can be increased when Lurasidone is combined with Adipiplon.	Investigational
Agomelatine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Agomelatine.	Approved, Investigational
AICA ribonucleotide	The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Lurasidone.	Experimental, Investigational
Alaproclate	The risk or severity of adverse effects can be increased when Lurasidone is combined with Alaproclate.	Experimental
Alfaxalone	The risk or severity of adverse effects can be increased when Lurasidone is combined with Alfaxalone.	Vet Approved
Alfentanil	The risk or severity of adverse effects can be increased when Alfentanil is combined with Lurasidone.	Approved, Illicit
Allicin	The therapeutic efficacy of Allicin can be decreased when used in combination with Lurasidone.	Investigational
Allopregnanolone	The risk or severity of adverse effects can be increased when Lurasidone is combined with Allopregnanolone.	Investigational
Almotriptan	The risk or severity of adverse effects can be increased when Almotriptan is combined with Lurasidone.	Approved, Investigational
Alogliptin	The therapeutic efficacy of Alogliptin can be decreased when used in combination with Lurasidone.	Approved
Alphacetylmethadol	The risk or severity of adverse effects can be increased when Lurasidone is combined with Alphacetylmethadol.	Experimental, Illicit
Alphaprodine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Alphaprodine.	Illicit
Alprazolam	The risk or severity of adverse effects can be increased when Alprazolam is combined with Lurasidone.	Approved, Illicit, Investigational
Amantadine	The therapeutic efficacy of Amantadine can be decreased when used in combination with Lurasidone.	Approved
Amiodarone	The serum concentration of Lurasidone can be increased when it is combined with Amiodarone.	Approved, Investigational
Amisulpride	Lurasidone may increase the antipsychotic activities of Amisulpride.	Approved, Investigational
Amitriptyline	The risk or severity of adverse effects can be increased when Lurasidone is combined with Amitriptyline.	Approved
Amobarbital	The risk or severity of adverse effects can be increased when Amobarbital is combined with Lurasidone.	Approved, Illicit
Amoxapine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Amoxapine.	Approved
Amperozide	The risk or severity of adverse effects can be increased when Lurasidone is combined with Amperozide.	Experimental
Amphetamine	Lurasidone may decrease the stimulatory activities of Amphetamine.	Approved, Illicit, Investigational
Apalutamide	The serum concentration of Lurasidone can be decreased when it is combined with Apalutamide.	Approved, Investigational
Apomorphine	The therapeutic efficacy of Apomorphine can be decreased when used in combination with Lurasidone.	Approved, Investigational
Aprepitant	The serum concentration of Lurasidone can be increased when it is combined with Aprepitant.	Approved, Investigational
Aripiprazole	The risk or severity of adverse effects can be increased when Aripiprazole is combined with Lurasidone.	Approved, Investigational
Articaine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Articaine.	Approved
Asenapine	The risk or severity of adverse effects can be increased when Asenapine is combined with Lurasidone.	Approved
Asunaprevir	The serum concentration of Asunaprevir can be increased when it is combined with Lurasidone.	Approved, Investigational, Withdrawn
Atazanavir	The serum concentration of Lurasidone can be increased when it is combined with Atazanavir.	Approved, Investigational
Atomoxetine	The serum concentration of Lurasidone can be increased when it is combined with Atomoxetine.	Approved
Atorvastatin	The risk or severity of adverse effects can be increased when Lurasidone is combined with Atorvastatin.	Approved
Azaperone	The risk or severity of adverse effects can be increased when Lurasidone is combined with Azaperone.	Investigational, Vet Approved
Azelastine	Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.	Approved
Baclofen	The risk or severity of adverse effects can be increased when Lurasidone is combined with Baclofen.	Approved
Balaglitazone	The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Lurasidone.	Investigational
Barbital	The risk or severity of adverse effects can be increased when Lurasidone is combined with Barbital.	Illicit
Bempedoic acid	The therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Lurasidone.	Investigational
Benperidol	The risk or severity of adverse effects can be increased when Lurasidone is combined with Benperidol.	Approved, Investigational
Benzocaine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Benzocaine.	Approved, Investigational
Benzphetamine	Lurasidone may decrease the stimulatory activities of Benzphetamine.	Approved, Illicit
Benzyl alcohol	The risk or severity of adverse effects can be increased when Lurasidone is combined with Benzyl alcohol.	Approved
Boceprevir	The serum concentration of Lurasidone can be increased when it is combined with Boceprevir.	Approved, Withdrawn
Bortezomib	The serum concentration of Lurasidone can be increased when it is combined with Bortezomib.	Approved, Investigational
Bosentan	The serum concentration of Lurasidone can be decreased when it is combined with Bosentan.	Approved, Investigational
Bosutinib	The serum concentration of Bosutinib can be increased when it is combined with Lurasidone.	Approved
Brexpiprazole	The risk or severity of adverse effects can be increased when Lurasidone is combined with Brexpiprazole.	Approved, Investigational
Brigatinib	The serum concentration of Lurasidone can be decreased when it is combined with Brigatinib.	Approved, Investigational
Brimonidine	Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.	Approved
Bromazepam	The risk or severity of adverse effects can be increased when Bromazepam is combined with Lurasidone.	Approved, Illicit, Investigational
Bromisoval	The risk or severity of adverse effects can be increased when Lurasidone is combined with Bromisoval.	Experimental
Bromocriptine	The risk or severity of adverse effects can be increased when Bromocriptine is combined with Lurasidone.	Approved, Investigational
Bromperidol	The risk or severity of adverse effects can be increased when Lurasidone is combined with Bromperidol.	Approved, Investigational
Brompheniramine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Brompheniramine.	Approved
Brotizolam	The risk or severity of adverse effects can be increased when Lurasidone is combined with Brotizolam.	Approved, Investigational, Withdrawn
Buformin	The therapeutic efficacy of Buformin can be decreased when used in combination with Lurasidone.	Investigational, Withdrawn
Bupivacaine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Bupivacaine.	Approved, Investigational
Buprenorphine	Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Buspirone	The risk or severity of adverse effects can be increased when Buspirone is combined with Lurasidone.	Approved, Investigational
Butabarbital	The risk or severity of adverse effects can be increased when Butabarbital is combined with Lurasidone.	Approved, Illicit
Butacaine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Butacaine.	Vet Approved
Butalbital	The risk or severity of adverse effects can be increased when Lurasidone is combined with Butalbital.	Approved, Illicit
Butamben	The risk or severity of adverse effects can be increased when Lurasidone is combined with Butamben.	Approved, Withdrawn
Butethal	The risk or severity of adverse effects can be increased when Lurasidone is combined with Butethal.	Approved, Illicit
Butorphanol	The risk or severity of adverse effects can be increased when Butorphanol is combined with Lurasidone.	Approved, Illicit, Vet Approved
Cabergoline	The risk or severity of adverse effects can be increased when Cabergoline is combined with Lurasidone.	Approved
Canagliflozin	The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lurasidone.	Approved
Canertinib	The risk or severity of adverse effects can be increased when Lurasidone is combined with Canertinib.	Investigational
Carbamazepine	The serum concentration of Lurasidone can be decreased when it is combined with Carbamazepine.	Approved, Investigational
Carbinoxamine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Carbinoxamine.	Approved
Carbutamide	The therapeutic efficacy of Carbutamide can be decreased when used in combination with Lurasidone.	Experimental
Carfentanil	The risk or severity of adverse effects can be increased when Lurasidone is combined with Carfentanil.	Illicit, Investigational, Vet Approved
Carisoprodol	The risk or severity of adverse effects can be increased when Lurasidone is combined with Carisoprodol.	Approved
Castanospermine	The therapeutic efficacy of Castanospermine can be decreased when used in combination with Lurasidone.	Experimental
Ceritinib	The serum concentration of Lurasidone can be increased when it is combined with Ceritinib.	Approved
Cerivastatin	The serum concentration of Cerivastatin can be increased when it is combined with Lurasidone.	Approved, Withdrawn
Cetirizine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Cetirizine.	Approved
Chloral hydrate	The risk or severity of adverse effects can be increased when Lurasidone is combined with Chloral hydrate.	Approved, Illicit, Investigational, Vet Approved
Chlordiazepoxide	The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Lurasidone.	Approved, Illicit, Investigational
Chlormezanone	The risk or severity of adverse effects can be increased when Lurasidone is combined with Chlormezanone.	Approved, Investigational, Withdrawn
Chloroprocaine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Chloroprocaine.	Approved
Chlorphenamine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Chlorphenamine.	Approved
Chlorphentermine	Lurasidone may decrease the stimulatory activities of Chlorphentermine.	Illicit, Withdrawn
Chlorpromazine	The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Lurasidone.	Approved, Investigational, Vet Approved
Chlorpropamide	The therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Lurasidone.	Approved, Investigational
Chlorprothixene	The risk or severity of adverse effects can be increased when Lurasidone is combined with Chlorprothixene.	Approved, Investigational, Withdrawn
Chlorzoxazone	The risk or severity of adverse effects can be increased when Lurasidone is combined with Chlorzoxazone.	Approved
Ciglitazone	The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Lurasidone.	Experimental
Cinchocaine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Cinchocaine.	Approved, Vet Approved
Citalopram	The risk or severity of adverse effects can be increased when Lurasidone is combined with Citalopram.	Approved
Clarithromycin	The serum concentration of Lurasidone can be increased when it is combined with Clarithromycin.	Approved
Clemastine	The serum concentration of Lurasidone can be increased when it is combined with Clemastine.	Approved, Investigational
Clidinium	The risk or severity of adverse effects can be increased when Lurasidone is combined with Clidinium.	Approved
Clobazam	The risk or severity of adverse effects can be increased when Lurasidone is combined with Clobazam.	Approved, Illicit
clomethiazole	The risk or severity of adverse effects can be increased when Lurasidone is combined with clomethiazole.	Investigational
Clomipramine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Clomipramine.	Approved, Investigational, Vet Approved
Clonazepam	The risk or severity of adverse effects can be increased when Lurasidone is combined with Clonazepam.	Approved, Illicit
Clonidine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Clonidine.	Approved
Clopenthixol	The risk or severity of adverse effects can be increased when Lurasidone is combined with Clopenthixol.	Experimental
Clorazepate	The risk or severity of adverse effects can be increased when Clorazepate is combined with Lurasidone.	Approved, Illicit
Clothiapine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Clothiapine.	Experimental
Clotrimazole	The serum concentration of Lurasidone can be increased when it is combined with Clotrimazole.	Approved, Vet Approved
Clozapine	The risk or severity of adverse effects can be increased when Clozapine is combined with Lurasidone.	Approved
Cobicistat	The serum concentration of Lurasidone can be increased when it is combined with Cobicistat.	Approved
Cocaine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Cocaine.	Approved, Illicit
Codeine	The risk or severity of adverse effects can be increased when Codeine is combined with Lurasidone.	Approved, Illicit
Conivaptan	The serum concentration of Conivaptan can be increased when it is combined with Lurasidone.	Approved, Investigational
Crizotinib	The serum concentration of Lurasidone can be increased when it is combined with Crizotinib.	Approved
Curcumin	The serum concentration of Lurasidone can be increased when it is combined with Curcumin.	Approved, Investigational
Cyclizine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Cyclizine.	Approved
Cyclobenzaprine	The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lurasidone.	Approved
Cyclopropane	The risk or severity of adverse effects can be increased when Lurasidone is combined with Cyclopropane.	Experimental
Cyclosporine	The serum concentration of Lurasidone can be increased when it is combined with Cyclosporine.	Approved, Investigational, Vet Approved
Cyproheptadine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Cyproheptadine.	Approved
Dabrafenib	The serum concentration of Lurasidone can be decreased when it is combined with Dabrafenib.	Approved, Investigational
Dantrolene	The risk or severity of adverse effects can be increased when Lurasidone is combined with Dantrolene.	Approved, Investigational
Dapiprazole	The risk or severity of adverse effects can be increased when Lurasidone is combined with Dapiprazole.	Approved
Dapoxetine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Dapoxetine.	Investigational
Darunavir	The serum concentration of Lurasidone can be increased when it is combined with Darunavir.	Approved
Dasatinib	The serum concentration of Lurasidone can be increased when it is combined with Dasatinib.	Approved, Investigational
Deferasirox	The serum concentration of Lurasidone can be decreased when it is combined with Deferasirox.	Approved, Investigational
Delavirdine	The serum concentration of Lurasidone can be increased when it is combined with Delavirdine.	Approved
Deoxyspergualin	The therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Lurasidone.	Investigational
Deramciclane	The risk or severity of adverse effects can be increased when Lurasidone is combined with Deramciclane.	Investigational
Desflurane	The risk or severity of adverse effects can be increased when Desflurane is combined with Lurasidone.	Approved
Desipramine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Desipramine.	Approved, Investigational
Desloratadine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Desloratadine.	Approved, Investigational
Desvenlafaxine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Desvenlafaxine.	Approved, Investigational
Detomidine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Detomidine.	Vet Approved
Deutetrabenazine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Deutetrabenazine.	Approved, Investigational
Dexbrompheniramine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Dexbrompheniramine.	Approved
Dexmedetomidine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Dexmedetomidine.	Approved, Vet Approved
Dextroamphetamine	Lurasidone may decrease the stimulatory activities of Dextroamphetamine.	Approved, Illicit
Dextromethorphan	The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Lurasidone.	Approved
Dextromoramide	The risk or severity of adverse effects can be increased when Lurasidone is combined with Dextromoramide.	Experimental, Illicit
Dextropropoxyphene	The risk or severity of adverse effects can be increased when Lurasidone is combined with Dextropropoxyphene.	Approved, Illicit, Investigational, Withdrawn
Dezocine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Dezocine.	Approved, Investigational
Diazepam	The risk or severity of adverse effects can be increased when Diazepam is combined with Lurasidone.	Approved, Illicit, Investigational, Vet Approved
Diethyl ether	The risk or severity of adverse effects can be increased when Lurasidone is combined with Diethyl ether.	Experimental
Diethylpropion	Lurasidone may decrease the stimulatory activities of Diethylpropion.	Approved, Illicit
Difenoxin	The risk or severity of adverse effects can be increased when Lurasidone is combined with Difenoxin.	Approved, Illicit
Dihydrocodeine	The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Lurasidone.	Approved, Illicit
Dihydroergocornine	The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Lurasidone.	Approved
Dihydroergocristine	The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Lurasidone.	Approved, Experimental
Dihydroergocryptine	The risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Lurasidone.	Experimental
Dihydroergotamine	The serum concentration of Lurasidone can be increased when it is combined with Dihydroergotamine.	Approved, Investigational
Dihydroetorphine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Dihydroetorphine.	Experimental, Illicit
Dihydromorphine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Dihydromorphine.	Experimental, Illicit
Diltiazem	The serum concentration of Lurasidone can be increased when it is combined with Diltiazem.	Approved, Investigational
Dimenhydrinate	The risk or severity of adverse effects can be increased when Lurasidone is combined with Dimenhydrinate.	Approved
Diphenhydramine	The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Lurasidone.	Approved, Investigational
Diphenoxylate	The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Lurasidone.	Approved, Illicit
Disopyramide	Lurasidone may increase the QTc-prolonging activities of Disopyramide.	Approved
Dixyrazine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Dixyrazine.	Experimental
Dopamine	Dopamine may increase the hypotensive activities of Lurasidone.	Approved
Doramectin	The risk or severity of adverse effects can be increased when Lurasidone is combined with Doramectin.	Vet Approved
Doxepin	The risk or severity of adverse effects can be increased when Lurasidone is combined with Doxepin.	Approved, Investigational
Doxycycline	The serum concentration of Lurasidone can be increased when it is combined with Doxycycline.	Approved, Investigational, Vet Approved
Doxylamine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.	Approved, Vet Approved
DPDPE	The risk or severity of adverse effects can be increased when Lurasidone is combined with DPDPE.	Experimental
Dronabinol	Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.	Approved, Illicit
Dronedarone	The serum concentration of Lurasidone can be increased when it is combined with Dronedarone.	Approved
Droperidol	Droperidol may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.	Approved, Vet Approved
Drotebanol	The risk or severity of adverse effects can be increased when Lurasidone is combined with Drotebanol.	Experimental, Illicit
Dulaglutide	The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Lurasidone.	Approved, Investigational
Duloxetine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Duloxetine.	Approved
Dyclonine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Dyclonine.	Approved
Ecgonine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Ecgonine.	Experimental, Illicit
Ecopipam	The risk or severity of adverse effects can be increased when Lurasidone is combined with Ecopipam.	Investigational
Efavirenz	The risk or severity of adverse effects can be increased when Lurasidone is combined with Efavirenz.	Approved, Investigational
Eletriptan	The risk or severity of adverse effects can be increased when Eletriptan is combined with Lurasidone.	Approved, Investigational
Eltanolone	The risk or severity of adverse effects can be increased when Lurasidone is combined with Eltanolone.	Investigational
Empagliflozin	The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lurasidone.	Approved
Enflurane	The risk or severity of adverse effects can be increased when Lurasidone is combined with Enflurane.	Approved, Investigational, Vet Approved
Englitazone	The therapeutic efficacy of Englitazone can be decreased when used in combination with Lurasidone.	Experimental
Entacapone	The risk or severity of adverse effects can be increased when Lurasidone is combined with Entacapone.	Approved, Investigational
Enzalutamide	The serum concentration of Lurasidone can be decreased when it is combined with Enzalutamide.	Approved
Epinephrine	Epinephrine may increase the hypotensive activities of Lurasidone.	Approved, Vet Approved
Ergoloid mesylate	The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Lurasidone.	Approved
Ergonovine	The risk or severity of adverse effects can be increased when Ergonovine is combined with Lurasidone.	Approved
Ergotamine	The risk or severity of adverse effects can be increased when Ergotamine is combined with Lurasidone.	Approved
Erythromycin	The serum concentration of Lurasidone can be increased when it is combined with Erythromycin.	Approved, Investigational, Vet Approved
Escitalopram	The risk or severity of adverse effects can be increased when Lurasidone is combined with Escitalopram.	Approved, Investigational
Estazolam	The risk or severity of adverse effects can be increased when Estazolam is combined with Lurasidone.	Approved, Illicit
Eszopiclone	The risk or severity of adverse effects can be increased when Eszopiclone is combined with Lurasidone.	Approved, Investigational
Ethanol	Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.	Approved
Ethchlorvynol	The risk or severity of adverse effects can be increased when Lurasidone is combined with Ethchlorvynol.	Approved, Illicit, Withdrawn
Ethosuximide	The risk or severity of adverse effects can be increased when Lurasidone is combined with Ethosuximide.	Approved
Ethotoin	The risk or severity of adverse effects can be increased when Lurasidone is combined with Ethotoin.	Approved
Ethyl carbamate	The risk or severity of adverse effects can be increased when Lurasidone is combined with Ethyl carbamate.	Withdrawn
Ethyl chloride	The risk or severity of adverse effects can be increased when Lurasidone is combined with Ethyl chloride.	Approved, Experimental, Investigational
Ethyl loflazepate	The risk or severity of adverse effects can be increased when Lurasidone is combined with Ethyl loflazepate.	Approved, Illicit
Ethylmorphine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Ethylmorphine.	Approved, Illicit
Etidocaine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Etidocaine.	Approved
Etifoxine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Etifoxine.	Investigational, Withdrawn
Etizolam	The risk or severity of adverse effects can be increased when Lurasidone is combined with Etizolam.	Approved
Etomidate	The risk or severity of adverse effects can be increased when Lurasidone is combined with Etomidate.	Approved
Etoperidone	The risk or severity of adverse effects can be increased when Lurasidone is combined with Etoperidone.	Withdrawn
Etorphine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Etorphine.	Illicit, Vet Approved
Exenatide	The therapeutic efficacy of Exenatide can be decreased when used in combination with Lurasidone.	Approved, Investigational
Ezogabine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Ezogabine.	Approved, Investigational
Felbamate	The risk or severity of adverse effects can be increased when Lurasidone is combined with Felbamate.	Approved
Fencamfamine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Fencamfamine.	Approved, Illicit, Withdrawn
Fentanyl	The risk or severity of adverse effects can be increased when Fentanyl is combined with Lurasidone.	Approved, Illicit, Investigational, Vet Approved
Fexofenadine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Fexofenadine.	Approved, Investigational
Flibanserin	The risk or severity of adverse effects can be increased when Lurasidone is combined with Flibanserin.	Approved, Investigational
Fluanisone	The risk or severity of adverse effects can be increased when Lurasidone is combined with Fluanisone.	Experimental
Fluconazole	The serum concentration of Lurasidone can be increased when it is combined with Fluconazole.	Approved, Investigational
Fludiazepam	The risk or severity of adverse effects can be increased when Lurasidone is combined with Fludiazepam.	Approved, Illicit
Flunarizine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Flunarizine.	Approved
Flunitrazepam	The risk or severity of adverse effects can be increased when Lurasidone is combined with Flunitrazepam.	Approved, Illicit
Fluoxetine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Fluoxetine.	Approved, Vet Approved
Flupentixol	The risk or severity of adverse effects can be increased when Flupentixol is combined with Lurasidone.	Approved, Investigational, Withdrawn
Fluphenazine	The risk or severity of adverse effects can be increased when Fluphenazine is combined with Lurasidone.	Approved
Flurazepam	The risk or severity of adverse effects can be increased when Flurazepam is combined with Lurasidone.	Approved, Illicit, Investigational
Fluspirilene	The risk or severity of adverse effects can be increased when Lurasidone is combined with Fluspirilene.	Approved, Investigational
Fluticasone propionate	The risk or severity of adverse effects can be increased when Lurasidone is combined with Fluticasone propionate.	Approved
Fluvastatin	The serum concentration of Fluvastatin can be increased when it is combined with Lurasidone.	Approved
Fluvoxamine	The serum concentration of Lurasidone can be increased when it is combined with Fluvoxamine.	Approved, Investigational
Fosamprenavir	The serum concentration of Lurasidone can be increased when it is combined with Fosamprenavir.	Approved
Fosaprepitant	The serum concentration of Lurasidone can be increased when it is combined with Fosaprepitant.	Approved
Fosphenytoin	The serum concentration of Lurasidone can be decreased when it is combined with Fosphenytoin.	Approved, Investigational
Fospropofol	The risk or severity of adverse effects can be increased when Lurasidone is combined with Fospropofol.	Approved, Illicit, Investigational
Frovatriptan	The risk or severity of adverse effects can be increased when Frovatriptan is combined with Lurasidone.	Approved, Investigational
Fusidic Acid	The serum concentration of Lurasidone can be increased when it is combined with Fusidic Acid.	Approved, Investigational
Gabapentin	The risk or severity of adverse effects can be increased when Gabapentin is combined with Lurasidone.	Approved, Investigational
Gabapentin Enacarbil	The risk or severity of adverse effects can be increased when Lurasidone is combined with Gabapentin Enacarbil.	Approved, Investigational
Gamma Hydroxybutyric Acid	The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Lurasidone.	Approved, Illicit, Investigational
Gepefrine	Lurasidone may decrease the stimulatory activities of Gepefrine.	Experimental
Gepirone	The risk or severity of adverse effects can be increased when Lurasidone is combined with Gepirone.	Investigational
Glibornuride	The therapeutic efficacy of Glibornuride can be decreased when used in combination with Lurasidone.	Investigational, Withdrawn
Gliclazide	The therapeutic efficacy of Gliclazide can be decreased when used in combination with Lurasidone.	Approved
Glimepiride	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Lurasidone.	Approved
Glipizide	The therapeutic efficacy of Glipizide can be decreased when used in combination with Lurasidone.	Approved, Investigational
Gliquidone	The therapeutic efficacy of Gliquidone can be decreased when used in combination with Lurasidone.	Approved, Investigational
Glutethimide	The risk or severity of adverse effects can be increased when Lurasidone is combined with Glutethimide.	Approved, Illicit
Glyburide	The therapeutic efficacy of Glyburide can be decreased when used in combination with Lurasidone.	Approved
Guanfacine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Guanfacine.	Approved, Investigational
Gusperimus	The therapeutic efficacy of Gusperimus can be decreased when used in combination with Lurasidone.	Investigational
Halazepam	The risk or severity of adverse effects can be increased when Lurasidone is combined with Halazepam.	Approved, Illicit, Withdrawn
Haloperidol	The risk or severity of adverse effects can be increased when Haloperidol is combined with Lurasidone.	Approved
Halothane	The risk or severity of adverse effects can be increased when Lurasidone is combined with Halothane.	Approved, Vet Approved
Heroin	The risk or severity of adverse effects can be increased when Lurasidone is combined with Heroin.	Approved, Illicit, Investigational
Hexobarbital	The risk or severity of adverse effects can be increased when Lurasidone is combined with Hexobarbital.	Approved
Hydrocodone	Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.	Approved, Illicit
Hydromorphone	The risk or severity of adverse effects can be increased when Hydromorphone is combined with Lurasidone.	Approved, Illicit
Hydroxyamphetamine	Lurasidone may decrease the stimulatory activities of Hydroxyamphetamine.	Approved
Hydroxyzine	Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.	Approved
Ibrutinib	The serum concentration of Ibrutinib can be increased when it is combined with Lurasidone.	Approved
Idelalisib	The serum concentration of Lurasidone can be increased when it is combined with Idelalisib.	Approved
Iloperidone	The risk or severity of adverse effects can be increased when Lurasidone is combined with Iloperidone.	Approved
Imatinib	The serum concentration of Lurasidone can be increased when it is combined with Imatinib.	Approved
Imipramine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Imipramine.	Approved
Indalpine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Indalpine.	Investigational, Withdrawn
Indinavir	The serum concentration of Lurasidone can be increased when it is combined with Indinavir.	Approved
Indiplon	The risk or severity of adverse effects can be increased when Lurasidone is combined with Indiplon.	Investigational
Insulin Aspart	The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Lurasidone.	Approved
Insulin Detemir	The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Lurasidone.	Approved
Insulin Glargine	The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Lurasidone.	Approved
Insulin Glulisine	The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Lurasidone.	Approved
Insulin Human	The therapeutic efficacy of Insulin Human can be decreased when used in combination with Lurasidone.	Approved, Investigational
Insulin Lispro	The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Lurasidone.	Approved
Insulin Pork	The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Lurasidone.	Approved
Iofetamine I-123	Lurasidone may decrease the stimulatory activities of Iofetamine I-123.	Approved
Isavuconazole	The serum concentration of Lurasidone can be increased when it is combined with Isavuconazole.	Approved, Investigational
Isavuconazonium	The serum concentration of Lurasidone can be increased when it is combined with Isavuconazonium.	Approved, Investigational
Isocarboxazid	The therapeutic efficacy of Lurasidone can be increased when used in combination with Isocarboxazid.	Approved
Isoflurane	The risk or severity of adverse effects can be increased when Isoflurane is combined with Lurasidone.	Approved, Vet Approved
Isradipine	The serum concentration of Lurasidone can be increased when it is combined with Isradipine.	Approved, Investigational
Itraconazole	The serum concentration of Lurasidone can be increased when it is combined with Itraconazole.	Approved, Investigational
Ivacaftor	The serum concentration of Lurasidone can be increased when it is combined with Ivacaftor.	Approved
Ketamine	The risk or severity of adverse effects can be increased when Ketamine is combined with Lurasidone.	Approved, Vet Approved
Ketazolam	The risk or severity of adverse effects can be increased when Lurasidone is combined with Ketazolam.	Approved
Ketobemidone	The risk or severity of adverse effects can be increased when Lurasidone is combined with Ketobemidone.	Approved, Investigational
Ketoconazole	The serum concentration of Lurasidone can be increased when it is combined with Ketoconazole.	Approved, Investigational
Lamotrigine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Lamotrigine.	Approved, Investigational
Levetiracetam	The risk or severity of adverse effects can be increased when Lurasidone is combined with Levetiracetam.	Approved, Investigational
Levobupivacaine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Levobupivacaine.	Approved, Investigational
Levocabastine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Levocabastine.	Approved, Investigational
Levocetirizine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Levocetirizine.	Approved
Levodopa	The therapeutic efficacy of Levodopa can be decreased when used in combination with Lurasidone.	Approved
Levomethadyl Acetate	The risk or severity of adverse effects can be increased when Lurasidone is combined with Levomethadyl Acetate.	Approved, Investigational
Levomilnacipran	The risk or severity of adverse effects can be increased when Lurasidone is combined with Levomilnacipran.	Approved, Investigational
Levorphanol	The risk or severity of adverse effects can be increased when Levorphanol is combined with Lurasidone.	Approved
Lidocaine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Lidocaine.	Approved, Vet Approved
Linagliptin	The therapeutic efficacy of Linagliptin can be decreased when used in combination with Lurasidone.	Approved
Linezolid	The risk or severity of adverse effects can be increased when Linezolid is combined with Lurasidone.	Approved, Investigational
Liraglutide	The therapeutic efficacy of Liraglutide can be decreased when used in combination with Lurasidone.	Approved
Lisdexamfetamine	Lurasidone may decrease the stimulatory activities of Lisdexamfetamine.	Approved, Investigational
Lisuride	The risk or severity of adverse effects can be increased when Lisuride is combined with Lurasidone.	Approved, Investigational
Lithium cation	Lithium may increase the neurotoxic activities of Lurasidone.	Experimental
Lofentanil	The risk or severity of adverse effects can be increased when Lurasidone is combined with Lofentanil.	Illicit
Lofexidine	The therapeutic efficacy of Lurasidone can be increased when used in combination with Lofexidine.	Approved, Investigational
Lopinavir	The serum concentration of Lurasidone can be increased when it is combined with Lopinavir.	Approved
Loprazolam	The risk or severity of adverse effects can be increased when Lurasidone is combined with Loprazolam.	Experimental
Loratadine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Loratadine.	Approved, Investigational
Lorazepam	The risk or severity of adverse effects can be increased when Lorazepam is combined with Lurasidone.	Approved
Lorcaserin	The risk or severity of adverse effects can be increased when Lorcaserin is combined with Lurasidone.	Approved
Lormetazepam	The risk or severity of adverse effects can be increased when Lurasidone is combined with Lormetazepam.	Approved
Lorpiprazole	The serum concentration of Lurasidone can be increased when it is combined with Lorpiprazole.	Approved
Lovastatin	The serum concentration of Lurasidone can be increased when it is combined with Lovastatin.	Approved, Investigational
Loxapine	The risk or severity of adverse effects can be increased when Loxapine is combined with Lurasidone.	Approved
Luliconazole	The serum concentration of Lurasidone can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The serum concentration of Lurasidone can be decreased when it is combined with Lumacaftor.	Approved
Lysergic Acid Diethylamide	The risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Lurasidone.	Illicit, Investigational, Withdrawn
Magnesium sulfate	The therapeutic efficacy of Lurasidone can be increased when used in combination with Magnesium sulfate.	Approved, Investigational, Vet Approved
Maprotiline	The risk or severity of adverse effects can be increased when Lurasidone is combined with Maprotiline.	Approved, Investigational
Mebicar	The risk or severity of adverse effects can be increased when Lurasidone is combined with Mebicar.	Experimental
Meclizine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Meclizine.	Approved
Medazepam	The risk or severity of adverse effects can be increased when Lurasidone is combined with Medazepam.	Experimental
Medetomidine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Medetomidine.	Vet Approved
Melatonin	The risk or severity of adverse effects can be increased when Lurasidone is combined with Melatonin.	Approved, Nutraceutical, Vet Approved
Melperone	The risk or severity of adverse effects can be increased when Lurasidone is combined with Melperone.	Approved, Investigational
Mephedrone	Lurasidone may decrease the stimulatory activities of Mephedrone.	Investigational
Mephentermine	Lurasidone may decrease the stimulatory activities of Mephentermine.	Approved
Mepivacaine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Mepivacaine.	Approved, Vet Approved
Meprobamate	The risk or severity of adverse effects can be increased when Meprobamate is combined with Lurasidone.	Approved, Illicit
Meptazinol	The risk or severity of adverse effects can be increased when Lurasidone is combined with Meptazinol.	Experimental
Mequitazine	Lurasidone may increase the arrhythmogenic activities of Mequitazine.	Approved
Mesoridazine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Mesoridazine.	Approved, Investigational
Metaxalone	The risk or severity of adverse effects can be increased when Lurasidone is combined with Metaxalone.	Approved
Metergoline	The risk or severity of adverse effects can be increased when Metergoline is combined with Lurasidone.	Experimental
Metformin	The therapeutic efficacy of Metformin can be decreased when used in combination with Lurasidone.	Approved
Methadone	The risk or severity of adverse effects can be increased when Methadone is combined with Lurasidone.	Approved
Methadyl Acetate	The risk or severity of adverse effects can be increased when Lurasidone is combined with Methadyl Acetate.	Approved, Illicit
Methamphetamine	Lurasidone may decrease the stimulatory activities of Methamphetamine.	Approved, Illicit
Methapyrilene	The risk or severity of adverse effects can be increased when Lurasidone is combined with Methapyrilene.	Withdrawn
Methaqualone	The risk or severity of adverse effects can be increased when Lurasidone is combined with Methaqualone.	Illicit, Withdrawn
Methocarbamol	The risk or severity of adverse effects can be increased when Lurasidone is combined with Methocarbamol.	Approved, Vet Approved
Methohexital	The risk or severity of adverse effects can be increased when Methohexital is combined with Lurasidone.	Approved
Methotrimeprazine	Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.	Approved, Investigational
Methoxyflurane	The risk or severity of adverse effects can be increased when Lurasidone is combined with Methoxyflurane.	Approved, Investigational, Vet Approved
Methoxyphenamine	Lurasidone may decrease the stimulatory activities of Methoxyphenamine.	Experimental
Methsuximide	The risk or severity of adverse effects can be increased when Lurasidone is combined with Methsuximide.	Approved
Methylecgonine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Methylecgonine.	Experimental
Methylergometrine	The risk or severity of adverse effects can be increased when Methylergometrine is combined with Lurasidone.	Approved
Methylphenidate	The risk or severity of adverse effects can be increased when Lurasidone is combined with Methylphenidate.	Approved, Investigational
Methylphenobarbital	The risk or severity of adverse effects can be increased when Lurasidone is combined with Methylphenobarbital.	Approved
Methysergide	The risk or severity of adverse effects can be increased when Methysergide is combined with Lurasidone.	Approved
Metoclopramide	The risk or severity of adverse effects can be increased when Metoclopramide is combined with Lurasidone.	Approved, Investigational
Metyrosine	Lurasidone may increase the sedative activities of Metyrosine.	Approved
Mevastatin	The serum concentration of Mevastatin can be increased when it is combined with Lurasidone.	Experimental
Midazolam	The risk or severity of adverse effects can be increased when Midazolam is combined with Lurasidone.	Approved, Illicit
Midomafetamine	Lurasidone may decrease the stimulatory activities of Midomafetamine.	Experimental, Illicit, Investigational
Mifepristone	The serum concentration of Lurasidone can be increased when it is combined with Mifepristone.	Approved, Investigational
Miglitol	The therapeutic efficacy of Miglitol can be decreased when used in combination with Lurasidone.	Approved
Miglustat	The therapeutic efficacy of Miglustat can be decreased when used in combination with Lurasidone.	Approved
Milnacipran	The risk or severity of adverse effects can be increased when Lurasidone is combined with Milnacipran.	Approved, Investigational
Minocycline	Minocycline may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.	Approved, Investigational
Mirtazapine	Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.	Approved
Mitiglinide	The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Lurasidone.	Approved, Investigational
Mitotane	The serum concentration of Lurasidone can be decreased when it is combined with Mitotane.	Approved
MMDA	Lurasidone may decrease the stimulatory activities of MMDA.	Experimental, Illicit
Moclobemide	The risk or severity of adverse effects can be increased when Moclobemide is combined with Lurasidone.	Approved, Investigational
Molindone	The risk or severity of adverse effects can be increased when Lurasidone is combined with Molindone.	Approved
Morphine	The risk or severity of adverse effects can be increased when Morphine is combined with Lurasidone.	Approved, Investigational
Nabilone	Nabilone may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.	Approved, Investigational
Nalbuphine	The risk or severity of adverse effects can be increased when Nalbuphine is combined with Lurasidone.	Approved
Naratriptan	The risk or severity of adverse effects can be increased when Naratriptan is combined with Lurasidone.	Approved, Investigational
Nateglinide	The therapeutic efficacy of Nateglinide can be decreased when used in combination with Lurasidone.	Approved, Investigational
Nefazodone	The serum concentration of Lurasidone can be increased when it is combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The serum concentration of Lurasidone can be increased when it is combined with Nelfinavir.	Approved
Netupitant	The serum concentration of Lurasidone can be increased when it is combined with Netupitant.	Approved, Investigational
Nevirapine	The serum concentration of Lurasidone can be decreased when it is combined with Nevirapine.	Approved
Nicergoline	The risk or severity of adverse effects can be increased when Nicergoline is combined with Lurasidone.	Approved, Investigational
Nilotinib	The serum concentration of Lurasidone can be increased when it is combined with Nilotinib.	Approved, Investigational
Nitrazepam	The risk or severity of adverse effects can be increased when Nitrazepam is combined with Lurasidone.	Approved
Nitrous oxide	The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Lurasidone.	Approved, Vet Approved
Nordazepam	The risk or severity of adverse effects can be increased when Lurasidone is combined with Nordazepam.	Approved
Norflurane	The risk or severity of adverse effects can be increased when Lurasidone is combined with Norflurane.	Approved, Investigational
Normethadone	The risk or severity of adverse effects can be increased when Lurasidone is combined with Normethadone.	Approved, Illicit
Nortriptyline	The risk or severity of adverse effects can be increased when Lurasidone is combined with Nortriptyline.	Approved
Olanzapine	The risk or severity of adverse effects can be increased when Olanzapine is combined with Lurasidone.	Approved, Investigational
Olaparib	The serum concentration of Lurasidone can be increased when it is combined with Olaparib.	Approved
Olopatadine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Olopatadine.	Approved
Ondansetron	The risk or severity of adverse effects can be increased when Lurasidone is combined with Ondansetron.	Approved
Opium	The risk or severity of adverse effects can be increased when Lurasidone is combined with Opium.	Approved, Illicit
Orphenadrine	Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.	Approved
Osanetant	The risk or severity of adverse effects can be increased when Lurasidone is combined with Osanetant.	Investigational
Osimertinib	The serum concentration of Lurasidone can be increased when it is combined with Osimertinib.	Approved
Oxazepam	The risk or severity of adverse effects can be increased when Oxazepam is combined with Lurasidone.	Approved
Oxprenolol	The risk or severity of adverse effects can be increased when Lurasidone is combined with Oxprenolol.	Approved
Oxybuprocaine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Oxybuprocaine.	Approved, Investigational
Oxycodone	The risk or severity of adverse effects can be increased when Oxycodone is combined with Lurasidone.	Approved, Illicit, Investigational
Oxymorphone	The risk or severity of adverse effects can be increased when Oxymorphone is combined with Lurasidone.	Approved, Investigational, Vet Approved
Palbociclib	The serum concentration of Lurasidone can be increased when it is combined with Palbociclib.	Approved, Investigational
Paliperidone	The risk or severity of adverse effects can be increased when Paliperidone is combined with Lurasidone.	Approved
Paraldehyde	Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.	Approved, Investigational
Paroxetine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Paroxetine.	Approved, Investigational
Penfluridol	The risk or severity of adverse effects can be increased when Lurasidone is combined with Penfluridol.	Experimental
Pentazocine	The risk or severity of adverse effects can be increased when Pentazocine is combined with Lurasidone.	Approved, Vet Approved
Pentobarbital	The serum concentration of Lurasidone can be decreased when it is combined with Pentobarbital.	Approved, Investigational, Vet Approved
Perampanel	Perampanel may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.	Approved
Perazine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Perazine.	Approved, Investigational
Pergolide	The risk or severity of adverse effects can be increased when Pergolide is combined with Lurasidone.	Approved, Investigational, Vet Approved, Withdrawn
Perospirone	The risk or severity of adverse effects can be increased when Lurasidone is combined with Perospirone.	Approved
Perphenazine	The risk or severity of adverse effects can be increased when Perphenazine is combined with Lurasidone.	Approved
Pethidine	The risk or severity of adverse effects can be increased when Pethidine is combined with Lurasidone.	Approved
Phenazocine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Phenazocine.	Experimental
Phenelzine	The risk or severity of adverse effects can be increased when Phenelzine is combined with Lurasidone.	Approved
Phenformin	The therapeutic efficacy of Phenformin can be decreased when used in combination with Lurasidone.	Approved, Investigational, Withdrawn
Phenibut	The risk or severity of adverse effects can be increased when Lurasidone is combined with Phenibut.	Experimental
Phenobarbital	The serum concentration of Lurasidone can be decreased when it is combined with Phenobarbital.	Approved, Investigational
Phenoperidine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Phenoperidine.	Experimental
Phenoxyethanol	The risk or severity of adverse effects can be increased when Lurasidone is combined with Phenoxyethanol.	Approved
Phentermine	Lurasidone may decrease the stimulatory activities of Phentermine.	Approved, Illicit
Phenytoin	The serum concentration of Lurasidone can be decreased when it is combined with Phenytoin.	Approved, Vet Approved
Pimozide	The risk or severity of adverse effects can be increased when Pimozide is combined with Lurasidone.	Approved
Pioglitazone	The therapeutic efficacy of Pioglitazone can be decreased when used in combination with Lurasidone.	Approved, Investigational
Pipamperone	The risk or severity of adverse effects can be increased when Lurasidone is combined with Pipamperone.	Approved, Investigational
Pipotiazine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Pipotiazine.	Approved, Investigational
Piribedil	The therapeutic efficacy of Piribedil can be decreased when used in combination with Lurasidone.	Investigational
Piritramide	The risk or severity of adverse effects can be increased when Lurasidone is combined with Piritramide.	Approved, Investigational
Pitavastatin	The serum concentration of Pitavastatin can be increased when it is combined with Lurasidone.	Approved
Pitolisant	The serum concentration of Lurasidone can be decreased when it is combined with Pitolisant.	Approved, Investigational
Pizotifen	The risk or severity of adverse effects can be increased when Lurasidone is combined with Pizotifen.	Approved
Pomalidomide	The risk or severity of adverse effects can be increased when Lurasidone is combined with Pomalidomide.	Approved
Posaconazole	The serum concentration of Lurasidone can be increased when it is combined with Posaconazole.	Approved, Investigational, Vet Approved
Pramipexole	Lurasidone may increase the sedative activities of Pramipexole.	Approved, Investigational
Pramlintide	The therapeutic efficacy of Pramlintide can be decreased when used in combination with Lurasidone.	Approved, Investigational
Pramocaine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Pramocaine.	Approved
Pravastatin	The serum concentration of Pravastatin can be increased when it is combined with Lurasidone.	Approved
Prazepam	The risk or severity of adverse effects can be increased when Lurasidone is combined with Prazepam.	Approved, Illicit
Pregabalin	The therapeutic efficacy of Lurasidone can be increased when used in combination with Pregabalin.	Approved, Illicit, Investigational
Prilocaine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Prilocaine.	Approved
Primidone	The serum concentration of Lurasidone can be decreased when it is combined with Primidone.	Approved, Vet Approved
Procainamide	Lurasidone may increase the QTc-prolonging activities of Procainamide.	Approved
Procaine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Procaine.	Approved, Investigational, Vet Approved
Procarbazine	The risk or severity of adverse effects can be increased when Procarbazine is combined with Lurasidone.	Approved, Investigational
Prochlorperazine	The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lurasidone.	Approved, Vet Approved
Promazine	The risk or severity of adverse effects can be increased when Promazine is combined with Lurasidone.	Approved, Vet Approved
Promethazine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Promethazine.	Approved, Investigational
Propanidid	The risk or severity of adverse effects can be increased when Lurasidone is combined with Propanidid.	Experimental
Proparacaine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Proparacaine.	Approved, Vet Approved
Propofol	The risk or severity of adverse effects can be increased when Propofol is combined with Lurasidone.	Approved, Investigational, Vet Approved
Propoxycaine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Propoxycaine.	Approved
Protriptyline	The risk or severity of adverse effects can be increased when Lurasidone is combined with Protriptyline.	Approved
Proxibarbal	The risk or severity of adverse effects can be increased when Lurasidone is combined with Proxibarbal.	Experimental
PSD502	The risk or severity of adverse effects can be increased when Lurasidone is combined with PSD502.	Investigational
Pseudoephedrine	Lurasidone may decrease the stimulatory activities of Pseudoephedrine.	Approved
Quazepam	The risk or severity of adverse effects can be increased when Quazepam is combined with Lurasidone.	Approved, Illicit
Quetiapine	The risk or severity of adverse effects can be increased when Quetiapine is combined with Lurasidone.	Approved
Quinagolide	The therapeutic efficacy of Quinagolide can be decreased when used in combination with Lurasidone.	Approved, Investigational
Quinidine	Lurasidone may increase the QTc-prolonging activities of Quinidine.	Approved, Investigational
Quinisocaine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Quinisocaine.	Experimental
Raclopride	The risk or severity of adverse effects can be increased when Lurasidone is combined with Raclopride.	Investigational
Ramelteon	The risk or severity of adverse effects can be increased when Lurasidone is combined with Ramelteon.	Approved, Investigational
Ranolazine	The serum concentration of Lurasidone can be increased when it is combined with Ranolazine.	Approved, Investigational
Rasagiline	The risk or severity of adverse effects can be increased when Rasagiline is combined with Lurasidone.	Approved
Remifentanil	The risk or severity of adverse effects can be increased when Remifentanil is combined with Lurasidone.	Approved
Remoxipride	The risk or severity of adverse effects can be increased when Lurasidone is combined with Remoxipride.	Approved, Withdrawn
Repaglinide	The therapeutic efficacy of Repaglinide can be decreased when used in combination with Lurasidone.	Approved, Investigational
Reserpine	The risk or severity of adverse effects can be increased when Reserpine is combined with Lurasidone.	Approved, Investigational
Ribociclib	The serum concentration of Lurasidone can be increased when it is combined with Ribociclib.	Approved, Investigational
Rifabutin	The serum concentration of Lurasidone can be decreased when it is combined with Rifabutin.	Approved, Investigational
Rifampicin	The serum concentration of Lurasidone can be decreased when it is combined with Rifampicin.	Approved
Rifapentine	The serum concentration of Lurasidone can be decreased when it is combined with Rifapentine.	Approved, Investigational
Rilpivirine	The serum concentration of Rilpivirine can be increased when it is combined with Lurasidone.	Approved
Risperidone	The risk or severity of adverse effects can be increased when Risperidone is combined with Lurasidone.	Approved, Investigational
Ritanserin	The risk or severity of adverse effects can be increased when Lurasidone is combined with Ritanserin.	Investigational
Ritobegron	Lurasidone may decrease the stimulatory activities of Ritobegron.	Investigational
Rizatriptan	The risk or severity of adverse effects can be increased when Rizatriptan is combined with Lurasidone.	Approved
Romifidine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Romifidine.	Vet Approved
Ropinirole	Lurasidone may increase the sedative activities of Ropinirole.	Approved, Investigational
Ropivacaine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Ropivacaine.	Approved
Rosiglitazone	The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Lurasidone.	Approved, Investigational
Rosuvastatin	The serum concentration of Rosuvastatin can be increased when it is combined with Lurasidone.	Approved
Rotigotine	Lurasidone may increase the sedative activities of Rotigotine.	Approved
Rucaparib	The serum concentration of Lurasidone can be increased when it is combined with Rucaparib.	Approved, Investigational
Rufinamide	The risk or severity of adverse effects can be increased when Rufinamide is combined with Lurasidone.	Approved
Saquinavir	The serum concentration of Lurasidone can be increased when it is combined with Saquinavir.	Approved, Investigational
Sarilumab	The therapeutic efficacy of Lurasidone can be decreased when used in combination with Sarilumab.	Approved, Investigational
Saxagliptin	The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Lurasidone.	Approved
Scopolamine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Scopolamine.	Approved, Investigational
Secobarbital	The risk or severity of adverse effects can be increased when Secobarbital is combined with Lurasidone.	Approved, Vet Approved
Selegiline	The risk or severity of adverse effects can be increased when Selegiline is combined with Lurasidone.	Approved, Investigational, Vet Approved
Sepranolone	The risk or severity of adverse effects can be increased when Lurasidone is combined with Sepranolone.	Investigational
Sertindole	The risk or severity of adverse effects can be increased when Lurasidone is combined with Sertindole.	Approved, Investigational, Withdrawn
Sertraline	The risk or severity of adverse effects can be increased when Lurasidone is combined with Sertraline.	Approved
Sevoflurane	The risk or severity of adverse effects can be increased when Sevoflurane is combined with Lurasidone.	Approved, Vet Approved
Sildenafil	The serum concentration of Lurasidone can be increased when it is combined with Sildenafil.	Approved, Investigational
Siltuximab	The serum concentration of Lurasidone can be decreased when it is combined with Siltuximab.	Approved, Investigational
Simeprevir	The serum concentration of Lurasidone can be increased when it is combined with Simeprevir.	Approved
Simvastatin	The serum concentration of Simvastatin can be increased when it is combined with Lurasidone.	Approved
Sitagliptin	The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Lurasidone.	Approved, Investigational
Sodium oxybate	Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.	Approved
Sotagliflozin	The therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Lurasidone.	Investigational
St. John's Wort	The serum concentration of Lurasidone can be decreased when it is combined with St. John's Wort.	Approved, Investigational, Nutraceutical
Stiripentol	The serum concentration of Lurasidone can be increased when it is combined with Stiripentol.	Approved
Sufentanil	The risk or severity of adverse effects can be increased when Sufentanil is combined with Lurasidone.	Approved, Investigational
Sulfisoxazole	The serum concentration of Lurasidone can be increased when it is combined with Sulfisoxazole.	Approved, Vet Approved
Sulodexide	The therapeutic efficacy of Sulodexide can be decreased when used in combination with Lurasidone.	Approved, Investigational
Sulpiride	Lurasidone may increase the antipsychotic activities of Sulpiride.	Approved, Investigational
Sultopride	The risk or severity of adverse effects can be increased when Lurasidone is combined with Sultopride.	Experimental
Sumatriptan	The risk or severity of adverse effects can be increased when Sumatriptan is combined with Lurasidone.	Approved, Investigational
Suvorexant	Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.	Approved, Investigational
Tandospirone	The risk or severity of adverse effects can be increased when Lurasidone is combined with Tandospirone.	Investigational
Tapentadol	Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.	Approved
Tasimelteon	The risk or severity of adverse effects can be increased when Lurasidone is combined with Tasimelteon.	Approved, Investigational
Tedizolid Phosphate	The risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Lurasidone.	Approved
Telaprevir	The serum concentration of Lurasidone can be increased when it is combined with Telaprevir.	Approved, Withdrawn
Telithromycin	The serum concentration of Lurasidone can be increased when it is combined with Telithromycin.	Approved
Temazepam	The risk or severity of adverse effects can be increased when Temazepam is combined with Lurasidone.	Approved, Investigational
Terguride	The risk or severity of adverse effects can be increased when Terguride is combined with Lurasidone.	Experimental
Tetrabenazine	The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Lurasidone.	Approved, Investigational
Tetracaine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Tetracaine.	Approved, Vet Approved
Tetrahydropalmatine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Tetrahydropalmatine.	Investigational
Tetrodotoxin	The risk or severity of adverse effects can be increased when Lurasidone is combined with Tetrodotoxin.	Investigational
Thalidomide	Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.	Approved, Investigational, Withdrawn
Thiamylal	The risk or severity of adverse effects can be increased when Lurasidone is combined with Thiamylal.	Approved, Vet Approved
Thiopental	The risk or severity of adverse effects can be increased when Lurasidone is combined with Thiopental.	Approved, Vet Approved
Thioridazine	The risk or severity of adverse effects can be increased when Thioridazine is combined with Lurasidone.	Approved, Withdrawn
Thiothixene	The risk or severity of adverse effects can be increased when Thiothixene is combined with Lurasidone.	Approved
Tiagabine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Tiagabine.	Approved, Investigational
Tiapride	The risk or severity of adverse effects can be increased when Lurasidone is combined with Tiapride.	Approved, Investigational
Ticlopidine	The serum concentration of Lurasidone can be increased when it is combined with Ticlopidine.	Approved
Tiletamine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Tiletamine.	Vet Approved
Tilidine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Tilidine.	Experimental
Tizanidine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Tizanidine.	Approved, Investigational
Tocilizumab	The serum concentration of Lurasidone can be decreased when it is combined with Tocilizumab.	Approved
Tolazamide	The therapeutic efficacy of Tolazamide can be decreased when used in combination with Lurasidone.	Approved, Investigational
Tolbutamide	The therapeutic efficacy of Tolbutamide can be decreased when used in combination with Lurasidone.	Approved, Investigational
Tolcapone	The risk or severity of adverse effects can be increased when Lurasidone is combined with Tolcapone.	Approved, Withdrawn
Tolvaptan	The serum concentration of Tolvaptan can be increased when it is combined with Lurasidone.	Approved
Topiramate	The risk or severity of adverse effects can be increased when Lurasidone is combined with Topiramate.	Approved
Tramadol	The risk or severity of adverse effects can be increased when Tramadol is combined with Lurasidone.	Approved, Investigational
Tranylcypromine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Tranylcypromine.	Approved, Investigational
Trazodone	The risk or severity of adverse effects can be increased when Lurasidone is combined with Trazodone.	Approved, Investigational
Triazolam	The risk or severity of adverse effects can be increased when Triazolam is combined with Lurasidone.	Approved, Investigational
Tricaine methanesulfonate	The risk or severity of adverse effects can be increased when Lurasidone is combined with Tricaine methanesulfonate.	Vet Approved
Trichloroethylene	The risk or severity of adverse effects can be increased when Lurasidone is combined with Trichloroethylene.	Approved
Trifluoperazine	The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Lurasidone.	Approved, Investigational
Trifluperidol	The risk or severity of adverse effects can be increased when Lurasidone is combined with Trifluperidol.	Experimental
Triflupromazine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Triflupromazine.	Approved, Vet Approved
Trimipramine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Trimipramine.	Approved
Triprolidine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Triprolidine.	Approved
Troglitazone	The therapeutic efficacy of Troglitazone can be decreased when used in combination with Lurasidone.	Investigational, Withdrawn
Valproic Acid	The risk or severity of adverse effects can be increased when Lurasidone is combined with Valproic Acid.	Approved, Investigational
Vemurafenib	The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Lurasidone.	Approved
Venlafaxine	The serum concentration of Lurasidone can be increased when it is combined with Venlafaxine.	Approved
Veralipride	The risk or severity of adverse effects can be increased when Lurasidone is combined with Veralipride.	Experimental
Verapamil	The serum concentration of Lurasidone can be increased when it is combined with Verapamil.	Approved
Vigabatrin	The risk or severity of adverse effects can be increased when Lurasidone is combined with Vigabatrin.	Approved
Vilazodone	The risk or severity of adverse effects can be increased when Vilazodone is combined with Lurasidone.	Approved
Vildagliptin	The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Lurasidone.	Approved, Investigational
Vinyl ether	The risk or severity of adverse effects can be increased when Lurasidone is combined with Vinyl ether.	Experimental
Voglibose	The therapeutic efficacy of Voglibose can be decreased when used in combination with Lurasidone.	Approved, Investigational
Voriconazole	The serum concentration of Lurasidone can be increased when it is combined with Voriconazole.	Approved, Investigational
Vortioxetine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Vortioxetine.	Approved, Investigational
Xenon	The risk or severity of adverse effects can be increased when Lurasidone is combined with Xenon.	Experimental
Xylazine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Xylazine.	Vet Approved
Zaleplon	The risk or severity of adverse effects can be increased when Zaleplon is combined with Lurasidone.	Approved, Illicit, Investigational
Ziconotide	The risk or severity of adverse effects can be increased when Lurasidone is combined with Ziconotide.	Approved
Zimelidine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Zimelidine.	Withdrawn
Ziprasidone	The serum concentration of Lurasidone can be increased when it is combined with Ziprasidone.	Approved
Zolazepam	The risk or severity of adverse effects can be increased when Lurasidone is combined with Zolazepam.	Vet Approved
Zolmitriptan	The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Lurasidone.	Approved, Investigational
Zolpidem	Lurasidone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.	Approved
Zonisamide	The risk or severity of adverse effects can be increased when Lurasidone is combined with Zonisamide.	Approved, Investigational
Zopiclone	The risk or severity of adverse effects can be increased when Zopiclone is combined with Lurasidone.	Approved
Zotepine	The risk or severity of adverse effects can be increased when Lurasidone is combined with Zotepine.	Approved, Investigational, Withdrawn
Zuclopenthixol	The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Lurasidone.	Approved, Investigational

Food Interactions

When taken with food, there is a two-fold increase in exposure and time to maximal concentration is increased by 0.5-1.5 hours.

References

General References

George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936]
Tarazi FI, Stahl SM: Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother. 2012 Sep;13(13):1911-22. doi: 10.1517/14656566.2012.712114. Epub 2012 Jul 31. [PubMed:22849428]

External Links

KEGG Drug: D04820
PubChem Compound: 213046
PubChem Substance: 175427100
ChemSpider: 184739
BindingDB: 85222
ChEBI: 70735
ChEMBL: CHEMBL1237021
PharmGKB: PA166129557
RxList: RxList Drug Page
Drugs.com: Drugs.com Drug Page
Wikipedia: Lurasidone

ATC Codes

N05AE05 — Lurasidone

AHFS Codes

28:16.08.04 — Atypical Antipsychotics

FDA label

Download (452 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Not Available	Male, Healthy Normal Subjects	1
1	Completed	Not Available	Metabolism / Pharmacokinetics	1
1	Completed	Not Available	Pharmacokinetics	1
1	Completed	Not Available	Schizophrenia Patients	1
1	Completed	Not Available	Schizophrenic Disorders	3
1	Completed	Basic Science	Schizophrenic Disorders	1
1	Completed	Treatment	Autism, Early Infantile / Schizophrenic Disorders	1
2	Completed	Treatment	Affective Disorders / Asperger's Syndrome / Autistic Disorder / Bipolar I Disorder / Bipolar II Disorder / Child Development Disorders, Pervasive / Psychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder / Severe Major Depression With Psychotic Features / Severe Mood Disorder With Psychotic Features / Single Episode Major Depression Without Psychotic Symptoms	1
2	Completed	Treatment	Schizophrenic Disorders	4
2	Not Yet Recruiting	Treatment	Schizophrenic Disorders	1
2	Recruiting	Treatment	Depression, Bipolar / Suicidal Ideas / Suicidal Ideation / Suicide, Attempted	1
2, 3	Not Yet Recruiting	Treatment	Depression, Bipolar / Suicidal Ideation	1
3	Active Not Recruiting	Treatment	Autism, Early Infantile / Depression, Bipolar / Schizophrenic Disorders	1
3	Active Not Recruiting	Treatment	Bipolar I Disorder	1
3	Active Not Recruiting	Treatment	Depression, Bipolar	1
3	Completed	Treatment	Autism, Early Infantile	1
3	Completed	Treatment	Bipolar Disorder (BD) / Schizophrenic Disorders	1
3	Completed	Treatment	Bipolar I Disorder	3
3	Completed	Treatment	Depression, Bipolar	5
3	Completed	Treatment	Major Depressive Disorder (MDD)	1
3	Completed	Treatment	Major Depressive Disorder With Mixed Features	1
3	Completed	Treatment	Schizoaffective Disorders / Schizophrenic Disorders	1
3	Completed	Treatment	Schizophrenic Disorders	10
3	Recruiting	Treatment	Bipolar Disorder (BD)	1
3	Withdrawn	Treatment	Major Depressive Disorder (MDD)	1
4	Completed	Treatment	Psychotic Disorder NOS	1
4	Completed	Treatment	Schizoaffective Disorders / Schizophrenic Disorders	1
4	Completed	Treatment	Schizophrenic Disorders	2
4	Not Yet Recruiting	Treatment	Schizophrenic Disorders	1
4	Recruiting	Treatment	Schizophrenic Disorders	1
4	Suspended	Treatment	Bipolar Disorder (BD) / Bipolar I / Bipolar II / Bipolar Spectrum Disorder / Mania	1
Not Available	Completed	Not Available	Bipolar Disorder (BD)	1
Not Available	Completed	Treatment	Depression, Bipolar	1
Not Available	Enrolling by Invitation	Not Available	Bipolar Disorder (BD)	1
Not Available	Recruiting	Not Available	Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) / Acute Bacterial Sinusitis (ABS) / Acute Decompensated Heart Failure (ADHF) / Acute Pyelonephritis / Adenovirus / Adjunct to general anesthesia therapy / Adrenal Insufficiency / Airway Swelling / Anaesthesia therapy / Anxiolysis / Arterial Hypotension / Autism, Early Infantile / Autistic Disorder / Bartonellosis / Benzodiazepine Withdrawal / Benzodiazepines / Bipolar Disorder (BD) / Bloodstream Infections / Bone and Joint Infections / Brain Swelling / Bronchospasm / Brucellosis / Cardiac Arrest / Central Nervous System Infections / Cholera / Chronic Bacterial Prostatitis / Community Acquired Pneumonia (CAP) / Complicated Urinary Tract Infections / Convulsions / Cyanide Poisoning / Cytomegalovirus Retinitis / Drug hypersensitivity reaction / Early-onset Schizophrenia Spectrum Disorders / Edema / Epilepsies / Feeling Anxious / Flu caused by Influenza / Gastroparesis / GYNAECOLOGICAL INFECTION / Headaches / Herpes Simplex Virus / High Blood Cholesterol Level / High Blood Pressure (Hypertension) / Hospital-acquired bacterial pneumonia / Hyperlipidemias / Infantile Hemangiomas / Infection NOS / Inflammatory Conditions / Inflammatory Reaction / Influenza Treatment or Prophylaxis / Inhalational Anthrax (Post-Exposure) / Intra-Abdominal Infections / Life-threatening Fungal Infections / Lower Respiratory Tract Infection (LRTI) / Meningitis, Bacterial / Migraines / Muscle Spasms / Nausea / Opioid Addiction / Pain / Plague / Pneumonia / Prophylaxis / Psittacosis / Q Fever / Reflux / Relapsing Fever / Rocky Mountain Spotted Fever / Schizophrenic Disorders / Sedation therapy / Seizures / Sepsis / Skeletal Muscle Spasms / Skin and Subcutaneous Tissue Bacterial Infections / Skin Structures and Soft Tissue Infections / Stable Angina (SA) / Thromboprophylaxis / Thrombosis / Trachoma / Treatment-resistant Schizophrenia / Tularemia / Typhus Fever / Uncomplicated Skin and Skin Structure Infections / Uncomplicated Urinary Tract Infections / Urinary Tract Infections (UTIs) / Vomiting / Withdrawal	1
Not Available	Unknown Status	Not Available	Schizophrenic Disorders	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage forms

Form	Route	Strength
Tablet	Oral	120 mg
Tablet	Oral	20 mg
Tablet	Oral	40 mg
Tablet	Oral	60 mg
Tablet	Oral	80 mg
Tablet, film coated	Oral	120 mg/1
Tablet, film coated	Oral	20 mg/1
Tablet, film coated	Oral	40 mg/1
Tablet, film coated	Oral	60 mg/1
Tablet, film coated	Oral	80 mg/1

Prices

Not Available

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US9174975	Yes	2006-12-25	2026-12-25
US9259423	Yes	2011-11-23	2031-11-23
US8729085	Yes	2006-11-26	2026-11-26
US5532372	Yes	1999-01-02	2019-01-02
US8883794	Yes	2006-11-26	2026-11-26
USRE45573	Yes	2005-12-23	2025-12-23
US9555027	No	2006-05-26	2026-05-26
US9815827	No	2004-02-20	2024-02-20
US9827242	No	2011-05-23	2031-05-23
US9907794	No	2006-05-26	2026-05-26

Properties

State

Solid

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.00789 mg/mL	ALOGPS
logP	5.25	ALOGPS
logP	4.56	ChemAxon
logS	-4.8	ALOGPS
pKa (Strongest Basic)	8.5	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	5	ChemAxon
Hydrogen Donor Count	0	ChemAxon
Polar Surface Area	56.75 Å²	ChemAxon
Rotatable Bond Count	5	ChemAxon
Refractivity	139.33 m³·mol^-1	ChemAxon
Polarizability	56.2 Å³	ChemAxon
Number of Rings	7	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	1.0
Blood Brain Barrier	+	0.9907
Caco-2 permeable	+	0.5257
P-glycoprotein substrate	Substrate	0.6029
P-glycoprotein inhibitor I	Inhibitor	0.6713
P-glycoprotein inhibitor II	Inhibitor	0.73
Renal organic cation transporter	Inhibitor	0.5487
CYP450 2C9 substrate	Non-substrate	0.7897
CYP450 2D6 substrate	Substrate	0.8918
CYP450 3A4 substrate	Substrate	0.5922
CYP450 1A2 substrate	Non-inhibitor	0.677
CYP450 2C9 inhibitor	Inhibitor	0.6714
CYP450 2D6 inhibitor	Non-inhibitor	0.8292
CYP450 2C19 inhibitor	Inhibitor	0.7439
CYP450 3A4 inhibitor	Non-inhibitor	0.7835
CYP450 inhibitory promiscuity	High CYP Inhibitory Promiscuity	0.8126
Ames test	Non AMES toxic	0.6477
Carcinogenicity	Non-carcinogens	0.8986
Biodegradation	Not ready biodegradable	0.9959
Rat acute toxicity	2.4051 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.6636
hERG inhibition (predictor II)	Inhibitor	0.5858

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

Taxonomy

Description: This compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
Kingdom: Organic compounds
Super Class: Organoheterocyclic compounds
Class: Diazinanes
Sub Class: Piperazines
Direct Parent: N-arylpiperazines
Alternative Parents: Aromatic monoterpenoids / Isoindolones / Benzothiazoles / Dialkylarylamines / N-alkylpiperazines / Aminothiazoles / Benzenoids / Pyrrolidine-2-ones / Imidolactams / N-substituted carboxylic acid imides
show 11 more
Substituents: N-arylpiperazine / Aromatic monoterpenoid / Monoterpenoid / Norbornane monoterpenoid / Isoindolone / 1,2-benzothiazole / Isoindoline / Isoindole or derivatives / Dialkylarylamine / N-alkylpiperazine
show 29 more
Molecular Framework: Aromatic heteropolycyclic compounds
External Descriptors: N-arylpiperazine, dicarboximide, bridged compound, 1,2-benzisothiazole (CHEBI:70735)

Targets

Details1. D(2) dopamine receptor

Kind: Protein
Organism: Human
Pharmacological action: Yes
Actions: Antagonist

General Function: Potassium channel regulator activity
Specific Function: Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name: DRD2
Uniprot ID: P14416
Uniprot Name: D(2) dopamine receptor
Molecular Weight: 50618.91 Da

References

George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936]

Details2. 5-hydroxytryptamine receptor 2A

Kind: Protein
Organism: Human
Pharmacological action: Yes
Actions: Antagonist

General Function: Virus receptor activity
Specific Function: G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name: HTR2A
Uniprot ID: P28223
Uniprot Name: 5-hydroxytryptamine receptor 2A
Molecular Weight: 52602.58 Da

References

George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936]

Details3. 5-hydroxytryptamine receptor 7

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Antagonist

General Function: Serotonin receptor activity
Specific Function: This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name: HTR7
Uniprot ID: P34969
Uniprot Name: 5-hydroxytryptamine receptor 7
Molecular Weight: 53554.43 Da

References

George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936]

Details4. 5-hydroxytryptamine receptor 1A

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Antagonist

General Function: Serotonin receptor activity
Specific Function: G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers...
Gene Name: HTR1A
Uniprot ID: P08908
Uniprot Name: 5-hydroxytryptamine receptor 1A
Molecular Weight: 46106.335 Da

References

George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936]

Details5. Alpha-2C adrenergic receptor

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Antagonist

General Function: Protein homodimerization activity
Specific Function: Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name: ADRA2C
Uniprot ID: P18825
Uniprot Name: Alpha-2C adrenergic receptor
Molecular Weight: 49521.585 Da

References

George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936]

Details6. Alpha-2A adrenergic receptor

Kind: Protein
Organism: Human
Pharmacological action: Unknown

General Function: Thioesterase binding
Specific Function: Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name: ADRA2A
Uniprot ID: P08913
Uniprot Name: Alpha-2A adrenergic receptor
Molecular Weight: 48956.275 Da

References

Tarazi FI, Stahl SM: Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother. 2012 Sep;13(13):1911-22. doi: 10.1517/14656566.2012.712114. Epub 2012 Jul 31. [PubMed:22849428]

Enzymes

Details1. Cytochrome P450 3A4

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Substrate

General Function: Vitamin d3 25-hydroxylase activity
Specific Function: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name: CYP3A4
Uniprot ID: P08684
Uniprot Name: Cytochrome P450 3A4
Molecular Weight: 57342.67 Da

References

George M, Amrutheshwar R, Rajkumar RP, Kattimani S, Dkhar SA: Newer antipsychotics and upcoming molecules for schizophrenia. Eur J Clin Pharmacol. 2013 Aug;69(8):1497-509. doi: 10.1007/s00228-013-1498-4. Epub 2013 Apr 2. [PubMed:23545936]

Drug created on July 24, 2011 11:04 / Updated on July 16, 2018 21:25

Lurasidone

Identification

Structure for DB08815 (Lurasidone)

Pharmacology

Interactions

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Taxonomy

Targets

References

References

References

References

References

References

Enzymes

References